Dr. Naidoo Discusses the Management of Immune-Related Adverse Events in Lung Cancer

Jarushka Naidoo, MBBCh
Published: Saturday, Mar 10, 2018



Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

In the past few years, there have been several guidelines published to assist physicians with diagnosing and identifying immune-related side effects. Pneumonitis is the most common irAE seen in patients with lung cancer, Naidoo says, and it can be difficult to discern the difference between pneumonitis and pneumonia or progression of lung cancer.

It is widely accepted practice now that patients receive a high-resolution CT scan, but they can have a chest xray to start. Patients who are symptomatic should be considered for a bronchoscopy with or without a lung biopsy in order to tell if a patient has pneumonitis.
 


Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

In the past few years, there have been several guidelines published to assist physicians with diagnosing and identifying immune-related side effects. Pneumonitis is the most common irAE seen in patients with lung cancer, Naidoo says, and it can be difficult to discern the difference between pneumonitis and pneumonia or progression of lung cancer.

It is widely accepted practice now that patients receive a high-resolution CT scan, but they can have a chest xray to start. Patients who are symptomatic should be considered for a bronchoscopy with or without a lung biopsy in order to tell if a patient has pneumonitis.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x